Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
CD19 CAR-NK Cells(The Second Hospital of Shandong University) in Acute Lymphoblastic Leukemia: NCT06596057 Clinical Landscape Report 2026
16 October 2026
NCT06596057 clinical landscape for Acute Lymphoblastic Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ipilimumab in Refractory Melanoma: NCT06594991 Clinical Landscape Report 2026
16 October 2026
NCT06594991 clinical landscape for Refractory Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cell(Acellytron Therapeutics) in Multiple Myeloma: NCT06594211 Clinical Landscape Report 2026
16 October 2026
NCT06594211 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Olanzapine in Nausea: NCT06588413 Clinical Landscape Report 2026
16 October 2026
NCT06588413 clinical landscape for Nausea: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Vevoctadekin in Recurrent Multiple Myeloma: NCT06588660 Clinical Landscape Report 2026
16 October 2026
NCT06588660 clinical landscape for Recurrent Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anifrolumab-FNIA in Systemic Lupus Erythematosus: NCT06594068 Clinical Landscape Report 2026
16 October 2026
NCT06594068 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SHR-2005 in Non-Muscle Invasive Bladder Neoplasms: NCT06588179 Clinical Landscape Report 2026
16 October 2026
NCT06588179 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Ipilimumab in Melanoma: NCT06587451 Clinical Landscape Report 2026
16 October 2026
NCT06587451 clinical landscape for Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tislelizumab in Adult Acute Myeloblastic Leukemia: NCT06586099 Clinical Landscape Report 2026
16 October 2026
NCT06586099 clinical landscape for Adult Acute Myeloblastic Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Fludarabine Phosphate in Refractory acute myeloid leukemia: NCT06609928 Clinical Landscape Report 2026
16 October 2026
NCT06609928 clinical landscape for Refractory acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Indocyanine Green in Dermatofibrosarcoma: NCT06610071 Clinical Landscape Report 2026
16 October 2026
NCT06610071 clinical landscape for Dermatofibrosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CLN-978 in Systemic Lupus Erythematosus: NCT06613360 Clinical Landscape Report 2026
16 October 2026
NCT06613360 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.